…together to boost the phase 3 trials of the latter’s AAV-GAD program for Parkinson’s disease. MeiraGTx will bank $200 million upfront. The two will form a joint venture, Hologen Neuro…
…metabolic diseases involving the liver. And NRG Therapeutics in the UK closed a small seed investment of around £490,000 (€570,000) in a bid to treat Parkinson’s disease. One interesting seed…
…Cerevel Therapeutics, a biotech focused on developing drugs to treat psychiatric and neurological disorders. However, the deal with Cerevel has spurred antitrust scrutiny as the latter has Parkinson’s and schizophrenia…
…sclerosis, Parkinson’s disease, and various other CNS diseases. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) AAV capsid discovery platform,…
…or dopaminergic neurons in the case of Parkinson’s disease. These cells shall then be transplanted into patients to replace their own cells that might be defective, reduced in number, or…
…the pipeline, including a phase I/II gene therapy for Parkinson’s disease, and another in phase I/II for the rare neuromuscular disease Pompe disease. Synpromics also has ongoing partnerships with big…
…its AI-enabled platform. In the discovery stage, it is developing drugs to treat Parkinson’s disease, schizophrenia, psoriasis, atopic dermatitis, Crohn’s disease, and ulcerative colitis. It also has a partnered ALS…
…into the market last year, and is used to detect signs of other neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), dementia, concussions and Parkinson’s disease, as well. Labcorp is among…
…risk for Parkinson’s disease. The study, published in Nature Medicine, showed mice fetuses with Gaucher disease that received an injection of the gene therapy were able to express the missing…
…AI chips that rewire us to treat conditions like Parkinson’s disease. The German firm CureVac started the development of a vaccine for the emerging viral disease Covid-19. CureVac’s candidate is…
…pipeline was built around four small-molecule-based drug candidates that aim to treat Parkinson’s disease and rare diseases, which are all presently in preclinical stages. Kite and Arcellx continue oncology partnership…
…is working in the field of mitochondrial biology to treat Parkinson’s, motor neuron disease and other neurodegenerative disorders, received a $5.8M Biomedical Catalyst (BMC) award to fund preclinical development of…